Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Nazende G. Tureli, Akif E. Tureli and Marc Schneider
Affiliation: Pharmaceutics and Biopharmacy, Philipps-Universität Marburg, D-35032 Marburg, Germany.
Cystic fibrosis (CF), a genetic lethal chronic disease, causes the body to produce abnormally thick and sticky
mucus. As a consequence following bacterial infections threaten ten thousands of people around the world every year.
Available tests enable early diagnosis of CF. Nevertheless, current treatments can only serve to improve patient’s quality
of life. Despite the fact that life span of CF patients is dramatically increased with comprehensive treatments during the
last decades, there is no ultimate prevention or cure for CF. Chronic respiratory infections are known to be the major
cause of morbidity and mortality. Since the airways provide direct access to these bacteria, it is an attractive target for
drug delivery against bacterial infections in CF lung. Current pulmonary treatments are, however, limited since reaching
the site of action is highly inhibited by the biofilm, which establishes an efficient obstacle for drug diffusion. Recent developments
in nanotechnology have led many researchers to study different types of nanoparticles and nanoformulations
for pulmonary drug delivery in the scope of providing a solution to current treatment bottlenecks. This review focuses on
the development of nanoparticulate antibiotic pulmonary drug delivery systems for the treatment of Pseudomonas aeruginosa
infected CF lungs.
Keywords: Antibiotic loaded nanoparticles, bacterial infection, nanoparticles, Pseudomonas aeruginosa, pulmonary nanoparticulate
Rights & PermissionsPrintExport